5-[4-chloro-3-(methylsulfonyl)phenyl]-4-methyl-1,3-thiazol-2-amine | 593959-38-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[4-chloro-3-(methylsulfonyl)phenyl]-4-methyl-1,3-thiazol-2-amine
• 英文别名: 5-(4-chloro-3-methanesulfonyl-phenyI)-4-methyl-thiazol-2-ylamine；5-(4-chloro-3-methanesulfonyl-phenyl)-4-methyl-thiazol-2-ylamine；5-(4-chloro-3-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-amine
• CAS: 593959-38-7
• 化学式: C₁₁H₁₁ClN₂O₂S₂
• 分子量: 302.806
• InChiKey: ZVMIGNWPXSUFMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-[4-chloro-3-(methylsulfonyl)phenyl]-4-methyl-1,3-thiazol-2-amine 在 盐酸 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 cyclopentyl N-({5-[4-chloro-3-(methylsulfonyl)phenyl]-4-methyl-1,3-thiazol-2-yl}carbamoyl)-L-serinate
  参考文献：
  名称：

  WO2007/129048

  摘要：

  公开号：
• 作为产物：
  描述：

  1-(4-chloro-3-methanesulfonyl-phenyl)-propan-2-one 在 溴 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 25.5h， 生成 5-[4-chloro-3-(methylsulfonyl)phenyl]-4-methyl-1,3-thiazol-2-amine
  参考文献：
  名称：

  WO2007/129048

  摘要：

  公开号：

文献信息

• [EN] 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS<br/>[FR] DERIVES DU 5-PHENYLTHIAZOL ET LEURS UTILISATIONS COMME INHIBITEURS DE LA PI3 KINASE
  申请人：NOVARTIS AG

  公开号：WO2003072557A1

  公开（公告）日：2003-09-04

  Compounds of Formula I in free or salt form, wherein R1,R2,R3,R4, and R5, have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I中的化合物以自由或盐形式存在，其中R1、R2、R3、R4和R5的含义如规范中所示，适用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的过程。
• 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
  申请人：Bruce Ian

  公开号：US20050119320A1

  公开（公告）日：2005-06-02

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 , R 4 and R 5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I的化合物，无论是自由形式还是盐形式，其中R1、R2、R3、R4和R5的含义如规范中所示，对于治疗由磷脂酰肌醇3-激酶介导的疾病是有用的。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE
  申请人：Moffat David Charles Festus

  公开号：US20100010057A1

  公开（公告）日：2010-01-14

  Compounds of formula (I) are inhibitors of P13 kinase activity, and useful in treatment of, inter alia, autoimmune, inflammatory and proliferative diseases: wherein: s is 0 or 1; U is hydrogen or halogen; X is —(C═O), an optionally substituted divalent phenylene, pyridinylene, pyrimidinylene, or pyrazinylene radical, or a bond; P is optionally substituted C 1 -C 6 alkyl and Z is —(CH 2 ) Z —X 1 -L 1 -NHCHR 1 R 2 ; or Z is optionally substituted C 1 -C 6 alkyl and P is —(CH 2 ) Z —X 1 -L 1 -NHCHR 1 R 2 ; R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid; X 1 is (i) a bond; —NR 4 C(═O)NR 5 — or —NR 4 S(═O) 2 —; or except when X is —(C═O)— (ii) —C(═O)—, —S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; and z and L1 are as defined in the specification.

  化合物式(I)的复合物是P13激酶活性的抑制剂，并可用于治疗自身免疫性、炎症性和增殖性疾病，其中：s为0或1；U为氢或卤素；X为-(C═O)、一个可选取代的二价苯撑基、吡啶撑基、嘧啶撑基或吡嗪撑基基团，或一个键；P为可选取代的C1-C6烷基，Z为-(CH2)Z-X1-L1-NHCHR1R2；或Z为可选取代的C1-C6烷基，P为-(CH2)Z-X1-L1-NHCHR1R2；R1为羧酸基(—COOH)或一个酯基，该酯基可被一个或多个细胞内羧酸酯酶水解为羧酸基；R2为自然或非天然α-氨基酸的侧链；X1为(i)一个键；-NR4C(═O)NR5-或-NR4S(═O)2-；或除非X为-(C═O)- (ii) -C(═O)-、-S(═O)2-或-S(═O)2NR4-，其中R4和R5独立地为氢或可选取代的C1-C6烷基；z和L1如规范中定义。
• 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS
  申请人：Bruce Ian

  公开号：US20100093690A1

  公开（公告）日：2010-04-15

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 , R 4 and R 5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I的化合物，无论是自由形式还是盐形式，其中R1、R2、R3、R4和R5的含义如规范中所示，对于治疗由磷脂酰肌醇3-激酶介导的疾病是有用的。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。
• METHODS FOR THE IDENTIFICATION OF PI3K INTERACTING MOLECULES AND FOR THE PURIFICATION OF PI3K
  申请人：Bergamini Moore Giovanna

  公开号：US20100055711A1

  公开（公告）日：2010-03-04

  The present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing a protein preparation containing PI3K, b) contacting the protein preparation with phenylthiazole ligand 1 immobilized on a solid support under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, c) incubating the phenylthiazole ligand 1-PI3K complex with a given compound, and d) determining whether the compound is able to separate PI3K from the immobilized phenylthiazole ligand 1. Furthermore, the present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing a protein preparation containing PI3K, b) contacting the protein preparation with phenylthiazole ligand 1 immobilized on a solid support and with a given compound under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, and c) detecting the phenylthiazole ligand 1-PI3K complex formed in step b). Furthermore, the present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing two aliquots of a protein preparation containing PI3K, b) contacting one aliquot with the phenylthiazole ligand 1 immobilized on a solid support under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, c) contacting the other aliquot with the phenylthiazole ligand 1 immobilized on a solid support and with a given compound under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, and d) determining the amount of the phenylthiazole ligand 1-PI3K complex formed in steps b) and c). Furthermore, the present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing two aliquots comprising each at least one cell containing PI3K, b) incubating one aliquot with a given compound, c) harvesting the cells of each aliquot, d) lysing the cells in order to obtain protein preparations, e) contacting the protein preparations with the phenylthiazole ligand 1 immobilized on a solid support under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, and f) determining the amount of the phenylthiazole ligand 1-PI3K complex formed in each aliquot in step e).

  本发明涉及一种用于鉴定PI3K相互作用化合物的方法，包括以下步骤：a）提供含有PI3K的蛋白制备物，b）在固定支持物上接触含有苯并噻唑配体1的蛋白制备物，在条件下允许形成苯并噻唑配体1-PI3K复合物，c）将苯并噻唑配体1-PI3K复合物与给定化合物孵育，d）确定该化合物是否能够将PI3K与固定的苯并噻唑配体1分离。此外，本发明还涉及一种用于鉴定PI3K相互作用化合物的方法，包括以下步骤：a）提供含有PI3K的蛋白制备物，b）在固定支持物上接触含有苯并噻唑配体1的蛋白制备物和给定化合物，在条件下允许形成苯并噻唑配体1-PI3K复合物，c）检测步骤b中形成的苯并噻唑配体1-PI3K复合物。此外，本发明还涉及一种用于鉴定PI3K相互作用化合物的方法，包括以下步骤：a）提供两个含有PI3K的蛋白制备物，b）将一个蛋白制备物与固定在支持物上的苯并噻唑配体1接触，在条件下允许形成苯并噻唑配体1-PI3K复合物，c）将另一个蛋白制备物与固定在支持物上的苯并噻唑配体1和给定化合物接触，在条件下允许形成苯并噻唑配体1-PI3K复合物，d）确定步骤b和c中形成的苯并噻唑配体1-PI3K复合物的数量。此外，本发明还涉及一种用于鉴定PI3K相互作用化合物的方法，包括以下步骤：a）提供至少一个含有PI3K的细胞的两个小分样，b）将一个小分样与给定化合物孵育，c）收集每个小分样的细胞，d）裂解细胞以获得蛋白制备物，e）在固定支持物上接触含有苯并噻唑配体1的蛋白制备物，在条件下允许形成苯并噻唑配体1-PI3K复合物，f）确定步骤e中每个小分样中形成的苯并噻唑配体1-PI3K复合物的数量。